BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.

Moderna is poised to commercialize the company’s COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against respiratory syncytial virus (RSV). 

Texas A&M University Science Center, MD Anderson Cancer Center, and Pulmotect report that the drug PUL-042 appears to work against COVID-19 and other respiratory infections.

Janssen Pharmaceutical’s experimental vaccine for a respiratory syncytial virus (RSV) demonstrated an 80 percent efficacy level in adults over the age of 65 years.

Moderna Inc. is developing a single vaccine that combines a booster dose against Covid-19 with the company’s experimental flu shot.

AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in healthy late preterm and term infants. RSV infections cause about 80,000 hospitalizations in children and 500 deaths each year. 

Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator.

Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants), which was cleared for Phase I trials, employs codon deoptimization to evoke a stronger-than-usual immune response.

Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.

Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of Covid-19 patients that is different from the type of immune cell activity found in other respiratory infections.